Liquidia Technologies: The New Champion in the Billion-Dollar Pulmonary Hypertension Market

Through its unique PRINT platform, Liquidia manufactures highly precise inhaled medications that are more effective and patient-friendly than traditional therapies. With its flagship product YUTREPIA™, Liquidia has successfully made the leap into profitability, as reflected in significant revenue increases and a first-ever positive cash flow. The company targets a billion-dollar market for rare lung diseases and is entering a significant scaling phase with its planned expansion into new treatment areas. Liquidia Technologies...